As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Tvardi Therapeutics, Inc. The largest reported stake is Sporos Bioventures LLC's, at 8.95%. 5 filings are on record since August 5, 2025 (Schedule 13G, August 8, 2025).
Who owns Tvardi Therapeutics, Inc.?
Sell to companies like Tvardi Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Ronald A. DePinho · Sole voting: 426,190 · Shared voting: 0 · Sole dispositive: 426,190 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-02-17
- · Holder: Ronald A. DePinho · Percent: 6.7% · SCHEDULE 13G/A
- · Reporting person: Slate Path Capital LP · Sole voting: 0 · Shared voting: 704,118 · Sole dispositive: 0 · Shared dispositive: 704,118 · SCHEDULE 13G, 2025-08-14
- · Reporting person: Sporos Bioventures LLC · Sole voting: 837,636 · Shared voting: 0 · Sole dispositive: 837,636 · Shared dispositive: 0 · SCHEDULE 13G, 2025-08-08
- · Holder: Samuel D. Tweardy · Percent: 3.4% · SCHEDULE 13G/A
Tvardi Therapeutics, Inc. has 5 Schedule 13D or 13G filings on record since 2025-08-05. 2 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Sporos Bioventures LLC | 8.95% | 837,636 | SCHEDULE 13G, 2025-08-08 | 2025-04-15 |
| Slate Path Capital LP | 7.5% | 704,118 | SCHEDULE 13G, 2025-08-14 | 2025-06-30 |
| 4.5% | 426,190 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 | |
| 3.4% | 315,658 | SCHEDULE 13G/A, 2025-08-05 | 2025-07-07 |
Holding shares or following this stake? See who's behind Tvardi Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Tvardi Therapeutics, Inc. and the records around it.
Tvardi Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- Slate Path Capital LP also filed stake reports on 2 other companies: WOLFSPEED, INC. (May 2026), Rocket Companies, Inc. (Oct 2025)
Watch Tvardi Therapeutics, Inc.
Get an email when Tvardi Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Tvardi Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Tvardi Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Tvardi Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Sporos Bioventures LLC | 837,636 | 0 | 837,636 | 0 | SCHEDULE 13G, 2025-08-08 |
| Slate Path Capital LP | 0 | 704,118 | 0 | 704,118 | SCHEDULE 13G, 2025-08-14 |
| David Greenspan | 0 | 704,118 | 0 | 704,118 | SCHEDULE 13G, 2025-08-14 |
| Ronald A. DePinho | 426,190 | 0 | 426,190 | 0 | SCHEDULE 13G/A, 2026-02-17 |
The latest filing names Tvardi Therapeutics, Inc., with its principal executive office as 3 Sugar Creek Ctr Blvd, Suite 525, Sugar Land, TX 77478 (SCHEDULE 13G/A, 2026-02-17).
What the percentages are based on
Row 11 of the Reporting Person's cover page to this Schedule 13G/A sets forth the percentage of the shares of common stock of the Issuer beneficially owned by the Reporting Person as of December 31, 2025 and is incorporated by reference.Ronald A. DePinho, SCHEDULE 13G/A, 2026-02-17
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-05 | Samuel D. Tweardy | 3.4% | SCHEDULE 13G/A |
| 2025-08-08 | Sporos Bioventures LLC | 8.95% | SCHEDULE 13G |
| 2025-08-14 | Slate Path Capital LP | 7.5% | SCHEDULE 13G |
| 2025-11-14 | Ronald A. DePinho | 6.7% | SCHEDULE 13G/A |
| 2026-02-17 | Ronald A. DePinho | 4.5% | SCHEDULE 13G/A |
Questions about who owns Tvardi Therapeutics, Inc.
Who owns Tvardi Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Tvardi Therapeutics, Inc.: Sporos Bioventures LLC (8.95%, Schedule 13G, filed 2025-08-08) and Slate Path Capital LP (7.5%, Schedule 13G, filed 2025-08-14).
Who are the largest shareholders of Tvardi Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Tvardi Therapeutics, Inc. on this page are Sporos Bioventures LLC (8.95%) and Slate Path Capital LP (7.5%).
When did Sporos Bioventures LLC buy into Tvardi Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Sporos Bioventures LLC on this page is the Schedule 13G, filed 2025-08-08, reporting 8.95%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Tvardi Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.